Immunization Action Coalition and the Hepatitis B Coalition

IAC EXPRESS

Previous issues index

Home page

Issue Number 322            July 8, 2002

CONTENTS OF THIS ISSUE

  1. CDC publishes notice on new acellular pertussis vaccine
  2. New Influenza Vaccine Information Statement is now available
  3. Dr. Julie Gerberding to head CDC
  4. New! Four more comprehensive Disease/Vaccine Information pages on IAC's website
  5. Going, going, but not gone! Popular "Immunization Techniques" video can still be ordered
  6. CMS satellite broadcast on vaccinating nursing home residents will take place August 16
  7. APHA annual meeting and exposition is scheduled for November 9-13
  8. Reminder: HFI hosts Hepatitis Summit July 18-19

----------------------------------------------------------

Back to Top

(1 of 8)
July 8, 2002
CDC PUBLISHES NOTICE ON NEW ACELLULAR PERTUSSIS VACCINE

On July 5, 2002, the Centers for Disease Control and Prevention (CDC) published "Notice to Readers: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants  and Young Children--United States, 2002" in the Morbidity and Mortality Weekly Report (MMWR).

The Notice reads in part as follows (excluding footnotes):

*******************************

On May 14, 2002, the Food and Drug Administration (FDA) approved for use an additional combined diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (DAPTACEL [TM] Aventis  Pasteur, Ltd. [Toronto, Ontario]) for the first 4 doses of the diphtheria and tetanus toxoids and pertussis vaccination (DTP) series administered to infants and children aged 6 weeks-6 years (before seventh  birthday). DAPTACEL is the fifth acellular pertussis vaccine to be licensed for use among infants and young children in the United States. Of these five, three (Tripedia[R], Infanrix[TM], and DAPTACEL[TM]) are distributed in the United States.

DAPTACEL is approved for administration as a 4-dose series at ages 2, 4, 6, and 17-20 months. The Advisory Committee on Immunization Practices (ACIP), the Committee on Infectious Diseases, the  American Academy of Pediatrics, and the American Academy of Family Physicians recommend that children routinely receive a series of 5 doses of vaccine against diphtheria, tetanus, and pertussis  before age 7 years. The first 4 doses should be administered at ages 2, 4, 6, and 15-18 months and the fifth dose at age 4-6 years. The customary age for the first dose is 2 months, but it may be given as early as age 6 weeks and up to the seventh birthday. The interval between the third and the fourth dose should be at least 6 months. Data are insufficient to evaluate the use of DAPTACEL as a fifth dose among children aged 4-6 years who have received DAPTACEL for the previous 4 doses. DAPTACEL may be used to complete the vaccination series in infants who have received 1 or more doses of whole-cell pertussis DTP. . . .

Whenever feasible, the same DTaP vaccine should be used throughout the entire vaccination series. Data are limited on the safety, immunogenicity, or efficacy of different DTaP vaccines when administered interchangeably in the primary or booster vaccination of a child. However, if the vaccine  provider does not know or have available the type of DTaP vaccine the child to be vaccinated had received previously, any of the licensed DTaP vaccines may be used to complete the vaccination series.

*******************************

To obtain the complete text of the Notice online, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5126a5.htm

To obtain a camera-ready (PDF format) copy of this issue of MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5126.pdf

HOW TO OBTAIN A FREE ELECTRONIC SUBSCRIPTION TO THE MMWR:
To obtain a free electronic subscription to the "Morbidity and Mortality Weekly Report" (MMWR), visit CDC's MMWR website at: http://www.cdc.gov/mmwr Select "Free MMWR Subscription" from the menu at the left of the screen. Once you have submitted the required information, weekly issues of the MMWR and all new ACIP statements (published as MMWR's "Recommendations and Reports") will arrive automatically by email.
----------------------------------------------------------

Back to Top

(2 of 8)
July 8, 2002
NEW INFLUENZA VACCINE INFORMATION STATEMENT IS NOW AVAILABLE

The Centers for Disease Control and Prevention (CDC) has issued a new Influenza Vaccine Information Statement (VIS) for 2002-2003. Dated 6/26/02, the new "flu VIS" features significant changes from the 2001-2002 version.

Of special note are changes in the sections "Who should get influenza vaccine?" and "When should I get influenza vaccine?" These and other sections reflect new recommendations as outlined in the April 12, 2002, statement from the Advisory Committee on Immunization Practices (ACIP), "Prevention and Control of Influenza" (MMWR; vol. 51, no. RR-3).

Don't forget that an annual flu shot is now encouraged for healthy children 6-23 months of age, when feasible, and their household contacts and out-of-home caretakers, as well as household contacts and  out-of-home caretakers of infants less than 6 months of age.

To obtain a copy of the Influenza VIS in camera-ready (PDF) format, use either of the two following links:
CDC: http://www.cdc.gov/nip/publications/VIS/vis-flu.pdf
IAC: http://www.immunize.org/vis/2flu.pdf

To obtain copies of all other VISs, including some in up to 27 languages, visit IAC's website at:
http://www.immunize.org/vis/

IAC's website also has links to CDC instructions on how to use VISs and their legal requirements. For "Vaccine Information Statements: What You Need to Know," go to:
http://www.immunize.org/vis/instr01.htm

For "Instructions for Use of Vaccine Information Statements," go to:
http://www.immunize.org/vis/instr2.pdf
----------------------------------------------------------

Back to Top

(3 of 8)
July 8, 2002
DR. JULIE GERBERDING TO HEAD CDC

On Wednesday, July 3, 2002, the U.S. Department of Health and Human Services announced the appointment of Julie L. Gerberding, M.D., M.P.H., as Director of the Centers for Disease Control and  Prevention (CDC). The full announcement reads as follows:

******************************

HHS Secretary Tommy G. Thompson today named Julie L. Gerberding, M.D., M.P.H., to be director of the Centers for Disease Control and Prevention (CDC) and administrator for the Agency for Toxic Substances and Disease Registry (ATSDR). Dr. Gerberding is an infectious disease expert and has been leading CDC's efforts to prepare for and counterterrorism. She assumes the post immediately.

Dr. Gerberding, 46, has been acting principal deputy director of CDC, and has served as part of the leadership team named to direct the agency since former director Dr. Jeffrey Koplan resigned March 31. She has also served as acting deputy director of CDC's National Center for Infectious Diseases.

"Dr. Gerberding knows public health, she knows infectious diseases, and she knows bioterrorism preparedness," Secretary Thompson said. "She brings the right mix of professional experience and leadership skills to ensure the CDC continues to meet the nation's public health needs."

Dr. Gerberding played a major role in leading CDC's response to the anthrax bioterrorism attacks last fall.

"The events of last fall made clear to all of us that this cannot be a time of business-as-usual," Dr. Gerberding said. "In a time of rapid change and growing responsibilities, CDC will ensure excellence in public health science, excellence in service to our public health partners and a sound organizational system to ensure that we fulfill our mission."

Dr. Gerberding joined the CDC in 1998 as director of the Division of Healthcare Quality Promotion, where she developed CDC's patient safety initiatives and other programs to prevent infections, antimicrobial resistance and medical errors in healthcare settings. Previously, she headed the Prevention Epicenter--a multidisciplinary service, teaching, and research program that focused on preventing infections in patients and their healthcare providers at the University of California, San Francisco (UCSF).

Dr. Gerberding earned her B.A. degree in chemistry and biology and M.D. degree at Case Western Reserve University in Cleveland, Ohio. She completed her internship and residency in internal medicine at UCSF, where she also served as chief medical resident at San Francisco General Hospital before  completing her National Institutes of Health (NIH) training fellowship in clinical pharmacology and infectious diseases at UCSF. She earned her Masters of Public Health (MPH) degree at the University of California, Berkeley, in 1990.

Dr. Gerberding is also a tenured associate professor of medicine and epidemiology and biostatistics at UCSF and an associate clinical professor of medicine at Emory University.

She is a native of South Dakota and is married to David A. Rose.

Secretary Thompson also praised the interim leadership team that steered CDC during the past three months. "During these months, the CDC remained focused on its essential missions, including an unprecedented rapid review of state bioterrorism preparedness plans required in issuing some $1.1 billion in grants to states," he said. "David Fleming and the other members of the interim team all  deserve credit for making the transition a smooth one."

The CDC is the nation's disease prevention agency, protecting people's health and safety, providing credible information to enhance health decisions, and improving health through strong partnerships. The agency includes 11 institutes, centers and offices, with nearly 8,600 employees. Its fiscal year 2002 budget is $6.8 billion.

******************************
----------------------------------------------------------

Back to Top

(4 of 8)
July 8, 2002
NEW! FOUR MORE COMPREHENSIVE DISEASE INFORMATION PAGES ON IAC'S WEBSITE

The "Diseases/Vaccines" section of IAC's website now contains individual web pages for 11 different diseases and the vaccines that prevent them. Links to all of these pages appear on the lefthand index bar on our home page.

The newest additions to this section are: the Hepatitis A Information page, the Haemophilus influenzae type b (Hib) Information page, the Influenza Information page, and the Polio Information page.

You will find these Disease/Vaccine Information pages very useful the next time you need answers to questions about outbreaks, vaccine recommendations, vaccine efficacy, state laws, case histories, and other issues.

To view IAC's Hepatitis A Information page, go to:
http://www.immunize.org/hepa

To view IAC's Hib Information page, go to:
http://www.immunize.org/hib

To view IAC's Influenza Information page, go to:
http://www.immunize.org/influenza

To view IAC's Polio Information page, go to:
http://www.immunize.org/polio
----------------------------------------------------------

Back to Top

(5 of 8)
July 8, 2002
GOING, GOING, BUT NOT GONE! POPULAR "IMMUNIZATION TECHNIQUES" VIDEO CAN STILL BE ORDERED

Since we first offered the video "Immunization Techniques: Safe, Effective, Caring" in IAC EXPRESS #273 in September 2001, IAC has sold more than 4,000 videotapes! Don't be the last immunization provider on your block to buy and show "Immunization Techniques"! Because this video was so well-received as a staff training tool and refresher course, we are announcing it once again as follows:

Every clinic in the United States that delivers vaccination services should have a copy of the 35-minute video titled "Immunization Techniques: Safe, Effective, Caring." Developed by the California Department of Health Services Immunization Branch in collaboration with a team of national experts, this video teaches best practices about how to administer intramuscular (IM) and subcutaneous (SC) vaccines to infants, children, and adults. It is designed for use as a "hands-on" instructional program for new staff  as well as a refresher course for experienced health professionals.

The video provides discussion of all the following:

Anatomic sites
Choice of needle size
Vaccines and routes of administration
How to "draw up" doses of vaccine from a vial

Infants, toddlers, kindergartners, and adults are vaccinated in the video to demonstrate these techniques.

The video comes with presenter's notes that include instructional objectives, pre- and post-tests, photos showing vaccination sites appropriate for infants and toddlers, and a skills checklist to help you document that your staff is well trained.

IAC distributes the video and presenter's notes at $15 per set (to U.S. addresses). California Distance Learning Health Network (CDLHN) offers it at $25 per set. The versions are the same except that IAC's video comes in a plain cardboard sleeve and the presenter's notes are printed in black and white, while CDLHN's video box and presenter's notes are printed in color. The videotape and text of presenter's notes are identical. CDLHN also has a Spanish version available.

Order online (U.S. addresses only) at: https://www.immunize.org/iztech

Alternatively, an IAC order form is available at: http://www.immunize.org/catg.d/2020a.pdf

Send your order payment (check, credit card information, or purchase order) to Immunization Action Coalition, 1573 Selby Ave., Ste. 234, St. Paul, MN 55104 and include your complete mailing information and phone number. You can fax your order with payment information to IAC at (651) 647-9131. If you are placing an order from outside the United States, please call IAC at (651) 647-9009 for pricing information.

To order through CDLHN, call (619) 594-3348, email cdlhn@projects.sdsu.edu, or visit CDLHN online at http://www.cdlhn.com/
----------------------------------------------------------

Back to Top

(6 of 8)
July 8, 2002
CMS SATELLITE BROADCAST ON VACCINATING NURSING HOME RESIDENTS WILL TAKE PLACE AUGUST 16

The Centers for Medicare and Medicaid Services (CMS) will broadcast and webcast the program "New Interpretive Guidelines for Vaccinating Nursing Home Residents" on Friday, August 16, 2002, 1:00 p.m. to 3:30 p.m. EST.

The targeted audience for this free program includes nursing home administrators, nursing home surveyors, medical directors, and nurses. The program may also benefit nurse practitioners, infection control practitioners, epidemiologists, physicians, physician assistants, and nursing home inspection personnel.

The educational program will be a mix of live discussion, pre-taped video, graphs, and data. A live question-and-answer session will be held with the moderator and panel.

For details on the satellite broadcast or internet access to the webcast, go to:
http://www.cms.hhs.gov/medlearn/broadcst.asp

If you have further questions, contact Jackie Harley by phone at (410) 786-7222 or email at jharley@cms.hhs.gov
----------------------------------------------------------

Back to Top

(7 of 8)
July 8, 2002
APHA ANNUAL MEETING AND EXPOSITION IS SCHEDULED FOR NOVEMBER 9-13

Early-bird registration ends August 30 for the 130th American Public Health Association (APHA) Annual Meeting and Exposition scheduled for November 9-13, 2002, in Philadelphia, Pennsylvania.

APHA members and others can save up to $50 by registering during the summer months.

More than 4,000 papers will be presented at the APHA meeting, and more than 600 booths will be geared toward public health professionals in the exhibition areas.

To read about the meeting and hotel accommodations and to register online, go to:
http://www.apha.org/meetings

If you have questions, contact APHA by phone at (202) 777-2742 or contact Laser Registration by phone at (514) 228-3009 (Canadian number) or email at apha@laser-registration.com
----------------------------------------------------------

Back to Top

(8 of 8)
July 8, 2002
REMINDER: HFI HOSTS HEPATITIS SUMMIT JULY 18-19

The Hepatitis Foundation International (HFI) is hosting this 2-day education and training conference for health providers at all levels, as well as for patient advocates and "all others working with people who are  affected or infected by hepatitis." The Hepatitis Summit, with the theme "Viral Hepatitis: An Emerged Epidemic," will take place July 18 and 19 in La Mirada, Los Angeles County, California.

Program topics include the epidemiology of viral hepatitis, sexual transmission and risks, and managing the coinfected HIV/HCV patient. Experts in the field of viral hepatitis will be present from the National Institutes of Health, the Centers for Disease Control and Prevention, the Huntington Medical Institutes, and other organizations. Continuing education credits are available.

To read about the summit online, go to: http://www.hepfi.org/pdfs/summitregistration.pdf

For more information, contact HFI by phone at (800) 891-0707. 

 

Immunization Action Coalition1573 Selby AvenueSt. Paul MN 55104
E-mail: admin@immunize.org Web: http://www.immunize.org/
Tel: (651) 647-9009Fax: (651) 647-9131

This page was updated on July 8, 2002